Clinical Trial: This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249879) titled 'This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.' on Nov. 13.

Brief Summary: This is a First-in-Human, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC subjects.

Study Start Date: Nov. 21

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Small Cell Lung Cancer

Intervention: DRUG: GC511B CAR-T Cell Injection

This product is a lentiviral gene-modified autologous chimeric antigen re...